The present application describes a device and related method for lyophilizing (freeze-drying) and storing a fluid. The device is a continually evolving, multi-section lyophilization container that evolves throughout the stages of filling, lyophilization, storage, reconstitution and infusion. The method is a means by which the device is manipulated throughout the lyophilization process. In embodiments of the instant application, lyophilization of the fluid occurs in situ within the multi-section lyophilization container.
Any suitable fluid may be lyophilized and stored using the devices and techniques described in this disclosure, including human and animal blood and related blood products, such as blood plasma.
The advantages of lyophilization and the relative benefits of storing and transporting lyophilized products have been known for many years. Unfortunately, several technical challenges must be addressed before lyophilization can enjoy greater adoption in the blood and blood related fields. One such challenge is that many methods use glass containers which tend to be large and breakable. In this respect, a flexible pouch would be an improvement. Further, current methods suffer from prolonged drying times resulting from restricted vapor transmission to the condenser of the lyophilizer. Another challenge is that current lyophilization techniques include pathways by which both the blood, and the technician, may be subject to contamination. A yet further challenge, specific to techniques utilizing a flexible container including a breathable membrane, is a limitation in vapor flow caused by a wetting and fouling (i.e., blocking) of the breathable membrane throughout the lyophilization process which leads to relatively slow lyophilization times. Additionally, current devices include an arrangement of breathable and non-breathable elements which fails to provide adequate total breathable surface area, resulting in underperformance.
Because of these and other problems associated with the state of the art, the traditional approach to freezing, storing and transporting frozen blood and blood products remains the approach most commonly deployed. Problematically, traditional freezing, storage and transportation of blood and blood products requires the blood to be maintained at a temperature that is typically −20° C. or below to maintain protein integrity. This, in turn, necessitates cold chain management which dramatically increases the costs and logistical hurdles associated with traditional methods. For example, cold chain management requires the implementation of systems and protocols capable of effectively processing orders and providing reliable transportation and delivery of frozen products that then require thawing prior to transfusion. These requirements can present significant challenges in developing regions suffering from lack of resources and lack of infrastructure capable of accommodating the complex requirements of the cold chain logistics just described. Often, the result is that patients in dire need of transfusion in developing regions perish. Accordingly, despite their predominance, traditional methods remain burdened by disadvantages, particularly in connection with blood requiring storage for long periods or requiring temperature-controlled transportation over large distances.
Consequently, a strong interest remains in lyophilization as an alternative to traditional methods for freezing, storing and transporting blood and blood products. A lyophilized blood product, such as plasma, may have much smaller mass than a traditional product, has a longer shelf life and does not require extensive cold chain management or lengthy thawing procedures. Additionally, since a lyophilized blood product can be easily and rapidly reconstituted at its point of use, a lyophilized blood product is often preferable in battlefield environments, in emergency response situations and in various clinical applications. For these and other reasons, there remains a need to improve current lyophilization devices and techniques in relation to blood and blood products.
Although specific embodiments of the present application are provided in view of these and other considerations, the specific problems discussed herein should not be interpreted as limiting the applicability of the embodiments of this disclosure in any way.
This summary is provided to introduce aspects of some embodiments of the present application in a simplified form and is not intended to comprise an exhaustive list of all critical or essential elements of the claimed invention, nor is it intended to limit the scope of the claims.
Embodiments provide for a multi-part lyophilization container. The container includes a front surface, a back surface, a non-breathable section including a port region, a breathable section including a breathable membrane, and an occlusion zone encompassing a boundary bridging the non-breathable section and the breathable section. The non-breathable section is configured to accommodate any of a liquid, a solid and a gas, whereas the breathable section is configured to accommodate only a gas.
In another aspect, provided is a method of lyophilizing a fluid in a multi-part container. The method includes creating a temporary seal dividing a non-breathable section of the container and a breathable section of the container, inputting a liquid into the non-breathable section of the container, freezing the liquid, opening the temporary seal to allow vapor flow between the non-breathable section of the container and the breathable section of the container, and adding heat energy to the frozen liquid under vacuum, wherein the breathable section is configured to accommodate only a gas.
Further embodiments of the present application include additional methods and devices and systems for lyophilizing fluids. The fluid may be any suitable liquid, including human or animal plasma.
Non-limiting and non-exhaustive embodiments are described with reference to the following figures.
The principles described in the present application may be further understood by reference to the following detailed description and the embodiments depicted in the accompanying drawings. Although specific features are shown and described below with respect to particular embodiments, the present application is not limited to the specific features or embodiments provided. Moreover, embodiments below may be described with respect to lyophilizing and storing human or animal blood or blood components; however, such descriptions are merely illustrative. Those of skill in the art will appreciate that embodiments of this disclosure may be used in connection with the lyophilization of any suitable liquid.
Embodiments of the present application refer to a closed, sterile container, including sterile fluid pathways, for lyophilizing and storing a fluid, thus obviating the need for a clean room. Moreover, embodiments described in this application may be implemented in conjunction with many conventional, commercially available lyophilizers, such as the EPIC Small Production Lyophilizer by Millrock Technology. Accordingly, the devices and techniques described in this application may be more widely distributed and widely accessible than are existing devices and techniques. Further advantages of the various enumerated embodiments are noted throughout this disclosure.
The terms “multi-part container,” “container,” “lyophilization container,” “multi-part lyophilization container,” and the like, are used interchangeably throughout this disclosure. Similarly, the term “breathable,” with respect to materials and membranes, may be used interchangeably with the term “semi-permeable.” The term “non-breathable” may be used interchangeably with the term “non-permeable.”
Referring to
As shown in
The overall length of the lyophilization container 100, denoted as “L,” including both the non-breathable section 102 and the breathable section 106, is approximately 50 cm. In embodiments, L may be any dimension suitable for placement of the container in a shelf lyophilizer or other lyophilizer, any dimension required to increase or decrease vapor flow resistance, or any dimension to increase or decrease the thickness of the frozen liquid, such as between 30 cm and 70 cm, or more preferably between 40 cm and 60 cm. The width of the container, denoted as “W,” is approximately 15 cm. In embodiments, W may any suitable dimension, such as between 10 cm and 20 cm, or more preferably, between 13 cm and 17 cm. In the example shown, the length of non-breathable section 102, measured from the midpoint of the occlusion zone 114, is approximately 28 cm. In embodiments, the length of non-breathable section 102 may be any suitable dimension, such as between 20 cm and 40 cm, or more preferably, between 24 cm and 32 cm. The length of breathable section 106, measured from the midpoint of the occlusion zone 114, is approximately 22 cm. In embodiments, the length of breathable section 106 may be any suitable dimension, such as between 10 cm and 30 cm, or more preferably, between 18 cm and 26 cm. The exemplary dimensions of 15 cm by 50 cm described above are suited to lyophilize approximately 300 ml of liquid plasma. The lyophilization of larger or smaller volumes would suggest different preferred dimensions.
Although
dimension may better facilitate temporarily sealing of the occlusion zone during the lyophilization process.
The “top” or “front” of the lyophilization container 100 shown is essentially identical to the “bottom” or “back” of the container 100. That is, each of the top and the bottom of the container includes non-breathable material of the non-breathable section and breathable membrane of the breathable section. In alternative embodiments, the breathable membrane comprises a continuous sheet including an isoclinal (i.e., hairpin) fold causing the breathable membrane to bridge a portion of the top or front surface and a portion of the bottom or back surface. In yet another alternative embodiment, the breathable section might comprise breathable membrane only on the top of the container or only on the bottom of the container. In operation, the lyophilization container 100 is typically placed on a lyophilizer shelf such that the bottom or back of the container faces the lyophilizer shelf That is, during lyophilization, a portion of each of the non-breathable section 102 and the breathable section 106, including breathable membrane, face the lyophilizer shelf. Non-breathable section 102 should be in sufficient direct or indirect thermal communication with the lyophilizer shelf to facilitate conductive and/or radiative heat transfer. In yet further embodiments, only the non-breathable section might be in contact with the shelf and the breathable section might reside off the shelf. In certain other embodiments, the lyophilization container may be disposed vertically within a lyophilization chamber.
In operation, lyophilization container 100 exchanges fluids via ports positioned in the port region 104 of non-breathable section 102. Fluid exchanges occur only during initial filling of the container with liquid plasma and during the post-lyophilization filling of the container with sterile water for reconstitution and transfusion into a patient. Both prior to, and after, the sublimation of the frozen fluid and removal of vapor during lyophilization, non-breathable section 102 and breathable section 106 are isolated from one another by a creation of an occlusion of the container in the occlusion zone 114 encompassing the transition between the non-breathable section 102 and breathable section 106. In this respect, the position of the occlusion within the occlusion zone 114 defines the boundary between non-breathable section 102 and breathable section 106.
Outer perimeter weld 112 defines the outer perimeter of the container and includes port region 104 of the non-breathable section 102. Outer perimeter weld 112 has an average width of approximately 7 mm. In embodiments; however, outer perimeter weld 112 may be any suitable width, such as between 2 mm and 12 mm, and may further be variable by up 3 mm along its length.
Inner membrane weld 110 surrounds the breathable membrane 108 within breathable section 106. Inner membrane weld 110 also has average width of approximately 7 mm; however, in embodiments, inner membrane weld 110 may be any suitable width, such as between 2 mm and 12 mm, variable by up 3 mm along its length.
Port region 104 is the portion of the outer perimeter weld 112 of non-breathable section 102 configured to incorporate one or more fluidic ports capable of forming a sterile fluid pathway between the lyophilization container and any of several other fluid containers. Port region 104 is also configured to facilitate transfusion to a patient.
In addition to encompassing the boundary between non-breathable section 102 and breathable section 106, occlusion zone 114 is adapted to facilitate the evolution of the container throughout its life cycle. Occlusion of the container 100 in the occlusion zone 114 creates a temporary impermeable or substantially impermeable seal, eliminating the fluid communication between the non-breathable section 102 and breathable section 106. In operation, an initial occlusion isolates non-breathable section 102 from the breathable section 106 prior to the introduction of fluid via ports in port region 104. Removal or opening of the occlusion upon formation of a frozen ice structure (i.e., a frozen fluid structure to be lyophilized) allows the container to resume its native state, thus restoring the original container cavity. In the restored state, the container again provides a generous, open pathway for vapor flow between the non-breathable section 102 and breathable section 106. The ability of the container to continually evolve in form and function ensures that no contact occurs between the subject fluid and the breathable section 106 by causing the subject liquid to be isolated and frozen in only the non-breathable section 102 and allowing only the vapor flow from sublimation and desorption to contact the breathable section 106. That is, embodiments of the present application are configured to create a continuous physical separation between the subject liquid and the breathable section 106. Accordingly, the non-breathable section 102 is adapted to accommodate any of a solid, a liquid or a gas, whereas the breathable section 106 is adapted to accommodate only a gas (i.e., a gas only section).
Occlusion zone 114 is approximately 3 cm in width; however, in embodiments, the occlusion zone may be between 1 cm and 5 cm wide, such as between 2 cm and 4 cm wide. The nearest edge of the occlusion zone is preferably positioned within 5 cm of the breathable membrane 108 of the breathable section 106, but may be positioned between 0.2 cm and 10 cm, such as between 3 cm and 7 cm, from the breathable membrane 108. The occlusion zone 114 should be sufficiently proximate to the breathable membrane 108 to ensure the efficient use of container materials and to minimize the distance that vapor must flow to exit the container, yet sufficiently distant from the breathable membrane 108 to allow for the creation of a permanent seam in non-breathable material between the occlusion and the breathable membrane post lyophilization. The creation of a permanent seam in non-breathable material between the occlusion and the breathable membrane material post-lyophilization creates a permanent seal, allowing for a permanent separation of container sections and the removal and disposal of the breathable section 106. Removal of the breathable section 106 is the final step in the evolution of the container. Removal of the breathable section 106 minimizes the volume and the mass of the final product, which is desirable for both transportation and storage. Additionally, removal of breathable section 106 transforms non-breathable section 102 into a more traditional container suitable for fluid transfusion into a patient.
In embodiments, a visual indication may demarcate the occlusion zone 114. For example, the occlusion zone 114 may be indicated by lines, by a color scheme, or by any other conventional means of visual indication. In embodiments, a choice of material or texture may indicate the position of the occlusion zone 114. For example, a textured surface may provide a visual position indication designed to indicate the position and boundaries of the occlusion zone 114. In exemplary embodiments, particular materials or textures may also be chosen for one, or both, of the inner or outer surfaces of container material in the occlusion zone 114 to provide improved sealing characteristics (e.g., smooth materials), to impart an improved ability of the materials to pull apart from one another, or to pull apart from ice formed during freezing of the subject fluid (e.g., textured materials). Notably, materials chosen for the occlusion zone 114 may be textured or smooth and may be like or dissimilar to one another. Material and design choices for the occlusion zone 114 should consider that an intermittent application and removal of an occlusion in the occlusion zone 114 must reliably result in the intermittent creation and removal of a temporary impermeable seal. However, it should be noted that in some circumstances, an occlusion may not be a perfectly impervious or hermetic barrier or seal. That is, in certain situations, minor or insubstantial leakage across an occlusion may be acceptable.
The creation of an occlusion of the container in the occlusion zone 114 may occur by any known means, such as by manual clamping, or by various automated or semi-automated means. Exemplary manual clamps may include, but are not limited to, screw clamps or bag clips that are in common usage. Various automated or semi-automated occlusion means may, for example, include mechanical compression means incorporated into the shelves of, or the shelf system of, a lyophilizer. In all cases, the means chosen for creating an occlusion must ensure that fluids input into the non-breathable section 102 via port region 104 do not contact breathable membrane 108 of breathable section 106 at any point.
In embodiments described throughout this disclosure, various additional features may also be included in non-breathable section 102. For instance, a section of relatively clear container material may be incorporated into non-breathable section 102 to allow visual inspection of the subject fluid before, during or after lyophilization.
In the embodiment shown in
Linear, low density polyethylene (LLDPE) may also be desirable for use as non-breathable material. LLDPE is preferable to certain other materials due to its favorable puncture and impact resistance and to its high tensile strength. For instance, as compared to LDPE, LLDPE exhibits superior flexibility and resistance to cracking, thus making it more suitable for certain thin film applications.
Materials selected for non-breathable material must maintain strength at low temperatures (e.g., −40° C. to −60° C.) as is required for lyophilization. Certain materials exhibiting a low surface energy and super-hydrophobicity may further be incorporated into the interior surface of the non-breathable section to facilitate an improved release of the ice structure from the inner surfaces of the container after freezing and before drying.
In embodiments, various additional or alternative plastic films may be incorporated into non-breathable section 102, or to all areas of the container with non-breathable material for a particular purpose or application. For example, materials may be implemented for any of improved impermeability, improved heat sealing characteristics or improved mechanical strength.
Referring to
As shown in
In various embodiments, HOD 208 may be a rigid or a semi-rigid fixture captured within, or fastened to the outside of, the breathable section of the lyophilization container 200. The exact position of the HOD 208 may vary. For example, the HOD 208 may be positioned entirely within the non-breathable section, or within a region of non-breathable material of the breathable section. Alternatively, HOD 208 may extend into portions of both non-breathable material and breathable material. In yet further embodiments, HOD 208 may be positioned and configured to assist in the creation of the temporary seal between bag sections. Preferably, HOD 208 is positioned proximate to the occlusion zone to minimize the distance between the HOD 208 and the placement of an occlusion in the occlusion zone 216. In the example shown, the nearest edge of HOD 208 is positioned approximately 2.5 cm from nearest edge of the occlusion zone 216. Nonetheless, HOD 208 placement may be further optimized according to a particular container 200 or occlusion zone 216 configuration.
Referring to
Non-breathable section 300 is comprised of the non-breathable material described above. The boundaries of non-breathable section 300 include outer perimeter weld 304, including port region 306, and the midpoint (i.e., estimated position of occlusion) of the occlusion zone. That is, when the container is occluded in the occlusion zone 310, non-breathable section 300 may be defined as the section of the container on the side of the occlusion that is non-breathable. When an occlusion is not present in the occlusion zone 310, the boundary of the non-breathable section may be approximated as the midpoint of the occlusion zone, as shown ion
Referring to
Ports 308 shown in
A docking port may be included to connect the lyophilization container with another fluid container, such as a blood pooling container or pooling container set. A docking port may further be used to introduce air or other gas into the lyophilization container. Air or other gas may, for example, be introduced to create a vapor space above the subject liquid or to regulate pH. An exemplary docking port comprises PVC tubing. In embodiments, however, dock port may include any suitable docking fixtures or tubing which are known in the art.
A reconstitution port may be included to accept an inflow of reconstitution fluid into the lyophilization container. An exemplary reconstitution port 308 may include a male or a female Luer-Lock type connection in order to prevent accidental misconnection. One example of such a connection is the Correct Connect® system that is a standardized connection system used in apheresis applications. In embodiments, various one-way valves and other means for providing an error proof connection may also be adapted for use with the reconstitution port 308. Notably, the type of connection used for reconstitution is particularly important. That is, the handling of reconstitution fluids entails the potential risk of a direct transfusion of the reconstitution fluid into the patient. Such an event constitutes a serious and immediate health hazard. For this reason, it is important that the reconstitution port and related connections be highly conspicuous and be incompatible with the other ports in order to avoid an occurrence of accidental misconnection.
Referring to
The boundaries of breathable section 400 include outer perimeter weld 402 and the midpoint (i.e., estimated position of occlusion) of the occlusion zone 412. That is, when the container is occluded in the occlusion zone 412, breathable section 400 may be defined as the section of the container on the side of the occlusion that is breathable. When an occlusion is not present in the occlusion zone 412, the boundary of the breathable section 400 may be approximated as the midpoint of the occlusion zone, as shown in
Breathable section 400 comprises breathable membrane 408 embedded within non-breathable material. Inner membrane weld 410 is a sterile seal defining the boundary between the breathable membrane and non-breathable material. Outer perimeter weld 402 is a sterile seal defining the outer perimeter of breathable section 400. Outer perimeter weld 402 includes HOD capture voids 404 for capturing HOD 406 within the container.
In certain embodiments, breathable membrane 408 may comprise only one material. In other embodiments, breathable membrane 408 may comprise two or more materials, for example, breathable membrane may comprise a membrane laminate consisting of a breathable membrane and a backing material. In embodiments comprising a laminate, membrane material may include an expanded polytetrafluoroethylene (PTFE). PTFE membranes are preferable to other membranes for several reasons. For instance, expanded PTFE provides a microstructure that may be precisely controlled, which results in the ability to obtain a desired a pore size distribution. Further, expanded PTFE is essentially inert, is operable across a large temperature range and can withstand harsh environments. For at least these reasons, expanded PTFE provides characteristics which are preferable in comparison to other materials.
An ideal pore size for an expanded PTFE membrane may be between 0.1 micron (μm) to 0.5 μm, such as 0.15 μm to 0.45 μm, or 0.2 μm to 0.3 μm. A PTFE membrane having pore sizes in this range exhibits relatively efficient vapor transmission characteristics while maintaining a sterile barrier capable of eliminating the ingress of contaminants.
A reinforcing material is designed to bond the breathable section 400 to the non-breathable section without impairing the functionality of the breathable membrane 406. The addition of a reinforcing material improves the structural integrity of the container. That is, the reinforcing material must bond with the breathable membrane, must bond with the non-breathable material, and must have a pore size that does not impede vapor transmission across the breathable membrane during lyophilization. Exemplary reinforcing materials are preferably a 50:50 polypropylene/polyethylene blend. In embodiments, however, preferable blend ratios may vary and may be between 40:60 and 60:40 polypropylene:polyethylene. Polypropylene backing materials are advantageous, inter alia, for their transition glass temperatures which are low enough to avoid material degradation during freezing at lyophilization temperatures, such as −40° C.
In embodiments comprising a laminate, various additional or alternative plastic films may be incorporated into the breathable membrane or to the backing material to impart desired characteristics, such as favorable heat sealing characteristics, improved permeability, or for overall mechanical strength.
Referring to
Incorporation of the elliptic HOD 500 creates a generous open region above a thin, uniform structure of ice. Preferably, the thin, uniform ice structure has a thickness of from 6 mm to 13 mm, such as 10 mm, to maximize the efficacy and efficiency of the container. Incorporating the HOD 500 assists in securing a generous vapor pathway between the non-breathable section and the breathable section and reduces overall vapor pressure in the container during sublimation. HOD 500 may also compliment the intermittent creation of occlusions (i.e., temporary impermeable or substantially impermeable seals) in the occlusion zone. For example, HOD 500 may impart a tautness to container material which improves the reliability or quality of an occlusion. HOD 500 may likewise assist in the pulling apart of occlusion zone surfaces throughout the removal of the occlusion, thereby facilitating a re-creation of the vapor pathway between container sections. The pulling apart of occlusion zone surfaces can be complicated by the existence of ice formed on, or directly adjacent to, the occlusion as a result of an inadvertent wetting of occlusion zone materials by the subject fluid prior to the freezing step. Such wetting may be caused during the filling step, or by movement of the container. In this respect, HOD may compliment other means employed to address problems associated with the pulling apart of occlusion zone surfaces described herein, including material and related texture choices.
In the embodiment shown, HOD 500 comprises a semi-rigid silicone. In embodiments, however, several other rigid or semi-rigid materials may be implemented. For example, PVC or certain other synthetic plastic polymers may be preferable HOD 500 material. In certain embodiments, semi-rigid materials may be incorporated for their ability to flex in response to an occlusion of the occlusion zone. In such embodiments, HOD may compress to some degree upon occlusion of the occlusion zone, and may rebound toward an original shape upon removal of the occlusion. Such shape-memory behavior may assist in the maintaining of an open region above the subject liquid or ice and in the creation of generous vapor pathway between container sections. This may be especially pronounced in embodiments combining a semi-rigid HOD with other flexible container materials.
The external height of HOD 500 shown in
Referring to
HOD capture void 600 is essentially an indentation or a void within outer perimeter weld 606 in which the HOD is securely captured. As shown, the void space 602 has a width which is slightly larger than the width of the HOD to accommodate the HOD. Sidewalls 604 are angled at approximately 45 degrees to the longitudinal axis of the outer perimeter weld. Void space 602 depth is approximately 4 mm.
In embodiments, each of the parameters of the HOD capture void 600 can be optimized. For instance, HOD void space 602 width may vary according to a particular container configuration and may be as much as 20 percent greater than the width of the HOD. Likewise, HOD void space 602 depth may vary. For example, HOD void space 602 depth may be between 1 mm and 6 mm, such as between 2 mm and 4 mm.
In embodiments, the design of HOD capture void 600 may also vary. For instance, sidewall 604 angle may be lesser or greater than 45 degrees. In some cases, the sidewalls 604 may be perpendicular to the longitudinal axis of the outer perimeter weld 606. In further embodiments, sidewall 604 angles may be dissimilar. Likewise, HOD void space 602 depth may vary along its length. That is, in embodiments, HOD capture void 600 may be asymmetrical or irregular.
Referring to
In the embodiment shown in
Dam 704 shown in
As noted, embodiments of the lyophilization container(s) described herein are configured to continually evolve as the lyophilization process moves through its cycle. Exemplary workflows included below describe the manner in which container embodiments may be manipulated to accomplish container evolution.
Referring to
In step 804, the introduction of fluid may be referred to as pre-loading. During preloading, between 250 ml to 500 ml of fluid (e.g., blood plasma) are input into the non-breathable section of the multi-part lyophilization container. The container is then placed horizontally on the shelf of a lyophilizer, “front” or “top” side upward facing.
In step 810, sublimation and desorption include the application of heat energy and vacuum. Preferable drying temperatures may range from −20° C. to −40° C., such as −25° C. Owing to the generous vapor pathway between container sections and the large surface area of breathable membrane in the breathable section, vapor from the ice structure escapes relatively freely from the container. This, in turn, results colder temperatures during lyophilization and therefore improved quality of the final dry product. In addition, a diminution in sublimation times as compared to conventional lyophilization techniques is realized. Further, embodiments result in reduced vapor pressures in, and an increase in mass transfer across, the breathable section, which may result in a sufficient drying of the ice structure solely during a single drying phase. That is, embodiments may obviate the need for the secondary drying phase of traditional 2-phase drying methods (i.e., desorption).
In step 812, an occlusion is made in the occlusion zone of the container, creating a temporary seal between the breathable section and the non-breathable section.
In step 814, a permanent seam is created, isolating the lyophilized cake in the non-breathable section. In the schematic shown, permanent seam step 814 is a discreet step. That is, an ancillary piece of equipment is used to create the permanent seam or seal. In further examples, permanent seam step 814 may be integrated into occlusion step 812. In such embodiments, the occlusion means (e.g., a clamp) may incorporate the permanent sealing means.
In step 816, the complete removal of the breathable section represents the final evolution of the container. Removal of the breathable section eliminates the potential for moisture and oxygen ingress into the dried product, thereby increasing shelf life and plasma stability. Additionally, the reduced size of the final lyophilizate container is more convenient for each of transportation, storage, reconstitution and infusion.
In further exemplary workflows, steps may be added to the workflow described in
Referring to
In step 914, the lyophilization container is backfilled to partial atmospheric pressure with pH regulating gas (e.g., CO2). In exemplary embodiments, backfill pressure is 65 Torr (or 65 mmHG) absolute pressure. In embodiments, backfill pressure may range from between 40 mmHG and 90 mmHG, such as between 60 mmHG and 70 mmHG. Once at partial atmospheric pressure, the container is occluded, and then permanently sealed in steps 916 and 918, respectively. Occlusion and/or sealing of the container while at a pressure lower than atmospheric pressure causes the container to collapse and reduce its volume when the container is exposed to atmospheric pressure. This process also secures the pH regulating gas in the non-breathable portion and prevents an ingress of oxygen and moisture into the container. Since the resultant container has been occluded and/or sealed at a pressure that is less than atmospheric pressure, and since final container volume will be in a reduced volume condition once the vacuum of the lyophilizer is removed, the final lyophilized product can be stored and transported more easily. Backfilling in this manner is particularly applicable to container embodiments having flexible materials or components since such a diminution of container volume would not be possible with a rigid, inflexible lyophilization container.
In the workflows described above, the means for creating the occlusion are not limited. For example, occlusion means may be integrated into the flexible container, or may be a reusable piece of equipment external to the container. In all embodiments, occlusion means must be capable of creating a temporary impermeable or substantially impermeable seal between the non-breathable section and the breathable section of the evolving multi-part lyophilization container.
The use of a physical barrier (e.g., a clamp) to segregate fluid in the non-breathable section from the breathable section according to workflows described above eliminates the potential for fluid contact with, and fouling of, the pores of breathable material in the breathable section. Fouling can disrupt the sublimation and desorption aspects of lyophilization, thereby increasing total lyophilization time and reducing the ability to obtain a viable lyophilizate. Accordingly, eliminating the potential for fouling leads to a relative increase in vapor flow which, in turn, results in faster freeze drying, a colder ice temperature during primary drying due to an increased sublimative cooling effect and increased retention of proteins and clotting factors.
Moreover, because the lyophilization container is a closed, sterile system including sterile fluid pathways, embodiments enable lyophilization to occur in both non-sterile environments and in remote locations. In this respect, for example, embodiments allow lyophilization to be performed on-site at an ordinary blood center as opposed to a traditional clean room facility. Container embodiments also allow flexibility for an operator to freeze and maintain a frozen inventory of plasma in a standard freezer, such as that found in typical blood bank settings. At a later time, this previously frozen plasma can be moved to the more specialized lyophilization instrument for sublimation and desorption. Such work flow flexibility results in improved blood logistics and work flow within the blood bank.
A further advantage of embodiments described herein is the ability to remove the non-breathable section of the lyophilization container post-lyophilization. Isolation and removal of the breathable section post-lyophilization results in the creation of a smaller, lighter aseptic container enclosing the final lyophilizate. The resultant container is also both flexible and highly portable. Moreover, since the breathable section is most vulnerable to moisture and oxygen ingress, its removal can be said to improve the shelf stability of the lyophilizate. The novel use of a temporary occlusion described herein makes this advantage possible. That is, in conventional systems utilizing glass containers, a stopper is mechanically applied to a glass lyophilization container prior to the opening of the lyophilizer in order to prevent an ingress of moisture and oxygen into the container. In contrast, present embodiments utilize the temporary occlusion to prevent an ingress of moisture and oxygen into the non-breathable portion of the container until a permanent seal can be made between non-breathable material portions of the front and back of the container.
The ability of embodiments herein to evolve container configuration, yet to remain a closed, sterile system throughout each phase of container lifecycle is highly unique and advantageous in the lyophilization space. That is, the present embodiments evolve to achieve significant advantages over conventional devices and methods during each of filling, lyophilization, transportation, storage, reconstitution and infusion. Accordingly, many of the attributes and advantages described herein are not possible using conventional devices and approaches, which do not evolve and which require a clean room environment. Importantly in this regard, the evolving, multi-part containers described herein should be further considered evolving, multi-function containers insofar as the type and arrangement of container elements allow the container to accomplish various functions throughout its lifecycle.
Notwithstanding the various specific embodiments enumerated in this disclosure, those skilled in the art will appreciate that a variety of modifications and optimizations could be implemented for particular applications. Additionally, the present application is not limited to the lyophilization of blood or blood products. That is, the principles of the present application may be applicable to the lyophilization of many fluids. Accordingly, various modifications and changes may be made in the arrangement, operation, and details of the methods and systems of the present application which will be apparent to those skilled in the art.
This patent application is a continuation application of, and claims priority to, U.S. patent application Ser. No. 16/154,976, entitled “Lyophilization Container and Method of Using Same,” filed in the U.S. Patent and Trademark Office on Oct. 9, 2018. U.S. patent application Ser. No. 16/154,976 claims priority to each of U.S. Provisional Patent Application No. 62/569,858, entitled “Lyophilization and Storage Container for Freeze Dried Blood Products,” filed in the U.S. Patent and Trademark Office on Oct. 9, 2017 and U.S. Provisional Patent Application No. 62/571,087, entitled “Lyophilization and Storage Container for Freeze Dried Blood Products,” filed in the U.S. Patent and Trademark Office on Oct. 11, 2017. U.S. patent application Ser. No. 16/154,976 and each of the above-identified provisional patent applications are hereby incorporated by reference in their entirety as if set forth herein in full.
The invention was made with government support under contract number H92222-16-C-0081 awarded by the United States Department of Defense. The government has certain rights in the invention.
Number | Name | Date | Kind |
---|---|---|---|
136036 | Craven | Feb 1873 | A |
1441570 | Fitzgerald | Jan 1923 | A |
1504225 | Fitzgerald | Aug 1924 | A |
1956784 | Allen | May 1934 | A |
2659986 | Hink, Jr. | Nov 1953 | A |
2704075 | Cherkin | Mar 1955 | A |
2767117 | Crawley | Oct 1956 | A |
2893843 | Adam, Jr. | Jul 1959 | A |
2912359 | Anigstein et al. | Nov 1959 | A |
3008879 | Harvill | Nov 1961 | A |
3024167 | Damasukus | Mar 1962 | A |
3057781 | Mace et al. | Oct 1962 | A |
3123443 | Smeby | Mar 1964 | A |
3187750 | Tenczar, Jr. | Jun 1965 | A |
3223593 | Aldrich et al. | Dec 1965 | A |
3228841 | Cohen et al. | Jan 1966 | A |
3229813 | Crowe, Jr. | Jan 1966 | A |
3236732 | Arquilla | Feb 1966 | A |
3247957 | Kemble | Apr 1966 | A |
3260648 | Fox | Jul 1966 | A |
3294523 | Morningstar | Dec 1966 | A |
3322634 | Fulthorpe | May 1967 | A |
3375824 | Krakauer | Apr 1968 | A |
3395210 | Lenahan et al. | Jul 1968 | A |
3423290 | Chappelle | Jan 1969 | A |
3453180 | Fraser, Jr. et al. | Jul 1969 | A |
3466249 | Anderson | Sep 1969 | A |
3468471 | Linder | Sep 1969 | A |
3490437 | Bakondy et al. | Jan 1970 | A |
3519572 | Kita | Jul 1970 | A |
3533934 | Armanini | Oct 1970 | A |
3537189 | Thompson | Nov 1970 | A |
3548051 | Hamilton | Dec 1970 | A |
3556760 | Bender et al. | Jan 1971 | A |
3565987 | Schuurs | Feb 1971 | A |
3571940 | Bender | Mar 1971 | A |
3573063 | Williams | Mar 1971 | A |
3574950 | Dantoni | Apr 1971 | A |
3607858 | Querry | Sep 1971 | A |
3627878 | Linsner | Dec 1971 | A |
3629142 | Marbach | Dec 1971 | A |
3674860 | Welter et al. | Jul 1972 | A |
3714345 | Hirata | Jan 1973 | A |
3717708 | Wada et al. | Feb 1973 | A |
3730843 | McKie, Jr. | May 1973 | A |
3799740 | Mincey | Mar 1974 | A |
3803299 | Nouel | Apr 1974 | A |
3831293 | Ingram et al. | Aug 1974 | A |
3859047 | Klein | Jan 1975 | A |
3922145 | Turner et al. | Nov 1975 | A |
3932943 | Briggs et al. | Jan 1976 | A |
3944665 | Galoian et al. | Mar 1976 | A |
3945523 | Wertlake | Mar 1976 | A |
3964865 | Das | Jun 1976 | A |
3973002 | Hagan et al. | Aug 1976 | A |
3987159 | Spona et al. | Oct 1976 | A |
3993585 | Pinto et al. | Nov 1976 | A |
4001944 | Williams | Jan 1977 | A |
4002739 | Turner et al. | Jan 1977 | A |
4035924 | Faure | Jul 1977 | A |
4045176 | Proksch et al. | Aug 1977 | A |
4049673 | Scheinberg | Sep 1977 | A |
4056484 | Heimburger | Nov 1977 | A |
4059491 | Iwasa et al. | Nov 1977 | A |
4080265 | Antonik | Mar 1978 | A |
4089944 | Thomas | May 1978 | A |
4109396 | Fraser | Aug 1978 | A |
4127502 | Mutti et al. | Nov 1978 | A |
4134943 | Knitsch | Jan 1979 | A |
4141856 | Dorwart, Jr. et al. | Feb 1979 | A |
4141887 | Seufert | Feb 1979 | A |
4155186 | Robinson | May 1979 | A |
4157383 | Sedlacek et al. | Jun 1979 | A |
4188318 | Shanbrom | Feb 1980 | A |
4189400 | Proksch et al. | Feb 1980 | A |
4202665 | Wenz et al. | May 1980 | A |
4218321 | Sasaki | Aug 1980 | A |
4249826 | Studievic et al. | Feb 1981 | A |
4284725 | Fennel, III et al. | Aug 1981 | A |
4287087 | Brinkhous et al. | Sep 1981 | A |
4298441 | Seidel et al. | Nov 1981 | A |
4323478 | Adams et al. | Apr 1982 | A |
4324685 | Louderback | Apr 1982 | A |
4330463 | Luijerink | May 1982 | A |
4333767 | Nass | Jun 1982 | A |
4337240 | Saklad | Jun 1982 | A |
4442655 | Stroetmann | Apr 1984 | A |
4456590 | Rubinstein | Jun 1984 | A |
4465774 | Huang et al. | Aug 1984 | A |
4495278 | Thomas | Jan 1985 | A |
4506455 | Rossi | Mar 1985 | A |
4543335 | Sommer et al. | Sep 1985 | A |
4581231 | Purcell et al. | Apr 1986 | A |
4595021 | Shimizu et al. | Jun 1986 | A |
4614795 | Chavin et al. | Sep 1986 | A |
4624927 | Fukushima et al. | Nov 1986 | A |
4650678 | Fuhge | Mar 1987 | A |
4664913 | Mielke | May 1987 | A |
4666725 | Yamashita et al. | May 1987 | A |
4687664 | Philapitsch et al. | Aug 1987 | A |
4716119 | Rehner et al. | Dec 1987 | A |
4722790 | Cawley et al. | Feb 1988 | A |
4730460 | Coelho | Mar 1988 | A |
4731330 | Hill et al. | Mar 1988 | A |
4746730 | De Ambrosi et al. | May 1988 | A |
4780314 | Graves | Oct 1988 | A |
4806343 | Carpenter et al. | Feb 1989 | A |
4812557 | Yasushi et al. | Mar 1989 | A |
4813210 | Masuda | Mar 1989 | A |
4850353 | Stasz et al. | Jul 1989 | A |
4874690 | Goodrich, Jr | Oct 1989 | A |
4877608 | Lee et al. | Oct 1989 | A |
4877741 | Babcock et al. | Oct 1989 | A |
4902287 | Carmen | Feb 1990 | A |
4904641 | Eibl | Feb 1990 | A |
4973327 | Goodrich, Jr | Nov 1990 | A |
4986998 | Yoo et al. | Jan 1991 | A |
4994057 | Carmen | Feb 1991 | A |
5043261 | Goodrich | Aug 1991 | A |
5045446 | Goodrich, Jr | Sep 1991 | A |
5059036 | Richison | Oct 1991 | A |
5059518 | Kortright et al. | Oct 1991 | A |
5061789 | Moller et al. | Oct 1991 | A |
5063178 | Toomey | Nov 1991 | A |
5073378 | Shoshan et al. | Dec 1991 | A |
5114004 | Isono | May 1992 | A |
5118795 | Rubinstein | Jun 1992 | A |
5129162 | Hemmersbach et al. | Jul 1992 | A |
5147803 | Enomoto | Sep 1992 | A |
5151500 | Wismer-Pedersen et al. | Sep 1992 | A |
5171661 | Goodrich, Jr | Dec 1992 | A |
5178884 | Goodrich | Jan 1993 | A |
5213814 | Goodrich, Jr | May 1993 | A |
5242792 | Rudolph et al. | Sep 1993 | A |
5257983 | Garyantes | Nov 1993 | A |
5260420 | Burnouf-Radosevich et al. | Nov 1993 | A |
5262325 | Zimmermann et al. | Nov 1993 | A |
5304383 | Eibl et al. | Apr 1994 | A |
5309649 | Bergmann | May 1994 | A |
5340592 | Goodrich, Jr | Aug 1994 | A |
5399670 | Bhattacharya et al. | Mar 1995 | A |
5411893 | Eden et al. | May 1995 | A |
5420250 | Lontz | May 1995 | A |
5425951 | Goodrich, Jr. | Jun 1995 | A |
5464471 | Whalen et al. | Nov 1995 | A |
5514123 | Adolf | May 1996 | A |
5514586 | Hottinger et al. | May 1996 | A |
5527260 | Kameyama | Jun 1996 | A |
5547873 | Magneson et al. | Aug 1996 | A |
5551781 | Wilkes | Sep 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5637345 | Lee et al. | Jun 1997 | A |
5648206 | Goodrich, Jr | Jul 1997 | A |
5651966 | Read et al. | Jul 1997 | A |
5656498 | Iijima | Aug 1997 | A |
5690963 | Spargo et al. | Nov 1997 | A |
5695764 | Bontemps | Dec 1997 | A |
5698535 | Geczy et al. | Dec 1997 | A |
5736313 | Spargo et al. | Apr 1998 | A |
5747268 | Herring et al. | May 1998 | A |
5750330 | Tometsko et al. | May 1998 | A |
5750657 | Edwardson et al. | May 1998 | A |
5759774 | Hackett | Jun 1998 | A |
5795571 | Cederholm-Wlliams et al. | Aug 1998 | A |
5831027 | McIntosh et al. | Nov 1998 | A |
5834418 | Brazeau et al. | Nov 1998 | A |
5837519 | Savage et al. | Nov 1998 | A |
5849473 | Cabrera | Dec 1998 | A |
5853388 | Semel | Dec 1998 | A |
5860222 | Leander | Jan 1999 | A |
5861311 | Maples et al. | Jan 1999 | A |
5891393 | Read et al. | Apr 1999 | A |
5919766 | Osterberg et al. | Jul 1999 | A |
5919935 | Platz et al. | Jul 1999 | A |
5928213 | Barney et al. | Jul 1999 | A |
5946931 | Lomax | Sep 1999 | A |
5968831 | Shukla et al. | Oct 1999 | A |
5985582 | Triscott | Nov 1999 | A |
6007529 | Gustafsson | Dec 1999 | A |
6034060 | Yamamoto et al. | Mar 2000 | A |
6060233 | Wiggins | May 2000 | A |
6132454 | Fellows | Oct 2000 | A |
6139878 | Summaria et al. | Oct 2000 | A |
6148536 | Iijima | Nov 2000 | A |
6187553 | Antignani et al. | Feb 2001 | B1 |
6199297 | Wisniewski | Mar 2001 | B1 |
6218195 | Gottschalk et al. | Apr 2001 | B1 |
6221575 | Roser | Apr 2001 | B1 |
6270985 | Gottschalk et al. | Aug 2001 | B1 |
6323036 | Chapoteau et al. | Nov 2001 | B1 |
6323037 | Lauto et al. | Nov 2001 | B1 |
6331557 | Brugnara et al. | Dec 2001 | B1 |
6346216 | Kent | Feb 2002 | B1 |
6350584 | Gottschalk et al. | Feb 2002 | B1 |
6358236 | DeFoggi et al. | Mar 2002 | B1 |
6358678 | Bakaltcheva et al. | Mar 2002 | B1 |
6372423 | Braun | Apr 2002 | B1 |
6381870 | Kohlman | May 2002 | B1 |
6398771 | Gustafsson | Jun 2002 | B1 |
6416717 | Suzuki et al. | Jul 2002 | B1 |
6472162 | Coelho et al. | Oct 2002 | B1 |
6517526 | Tamari | Feb 2003 | B1 |
6566504 | Bhattacharya et al. | May 2003 | B2 |
6608237 | Li | Aug 2003 | B1 |
RE38431 | Miekka et al. | Feb 2004 | E |
6773425 | Tamari | Aug 2004 | B1 |
6852540 | Makiuchi et al. | Feb 2005 | B2 |
6869901 | Lubker, II | Mar 2005 | B2 |
6872576 | McIntyre | Mar 2005 | B1 |
6887852 | Paik et al. | May 2005 | B1 |
6890512 | Roser et al. | May 2005 | B2 |
6981337 | Jones | Jan 2006 | B2 |
7041635 | Kim et al. | May 2006 | B2 |
7048709 | Goudaliez | May 2006 | B2 |
7112320 | Beaulieu et al. | Sep 2006 | B1 |
7175614 | Gollier | Feb 2007 | B2 |
7179951 | Krishnaswamy-Mirle | Feb 2007 | B2 |
7202341 | McGinnis | Apr 2007 | B2 |
7249880 | Zambaux | Jul 2007 | B2 |
7343696 | Covert | Mar 2008 | B2 |
7358039 | Fischer et al. | Apr 2008 | B2 |
7363726 | Wang | Apr 2008 | B2 |
7411038 | Haynie | Aug 2008 | B2 |
7422726 | Hammerstedt | Sep 2008 | B2 |
7435795 | McGinnis | Oct 2008 | B2 |
7473246 | Vancaillie | Jan 2009 | B2 |
7480032 | Braig et al. | Jan 2009 | B2 |
7482020 | Hennessy et al. | Jan 2009 | B2 |
7501493 | Roser | Mar 2009 | B2 |
7569184 | Wandell et al. | Aug 2009 | B2 |
7618406 | Roger | Nov 2009 | B2 |
7678888 | Friedman et al. | Mar 2010 | B2 |
7727743 | Bardat et al. | Jun 2010 | B2 |
7776022 | McCarthy | Aug 2010 | B2 |
7811558 | Ho et al. | Oct 2010 | B2 |
7879332 | Zurlo et al. | Feb 2011 | B2 |
7931919 | Bakaltcheva | Apr 2011 | B2 |
7966746 | Py | Jun 2011 | B2 |
8013022 | DeAngelo | Sep 2011 | B2 |
8053248 | Bakaltcheva | Nov 2011 | B2 |
8057872 | Chen | Nov 2011 | B2 |
8097403 | Ho | Jan 2012 | B2 |
8187475 | Hecker et al. | May 2012 | B2 |
8235965 | Roger | Aug 2012 | B2 |
8236355 | Eijkenboom | Aug 2012 | B2 |
8268362 | Braun et al. | Sep 2012 | B2 |
8277837 | Fischer et al. | Oct 2012 | B2 |
8313654 | Piazza et al. | Nov 2012 | B2 |
8372343 | Goldstein | Feb 2013 | B2 |
8377882 | Schneider | Feb 2013 | B2 |
8407912 | Hubbard, Jr. et al. | Apr 2013 | B2 |
8430970 | Swami et al. | Apr 2013 | B2 |
8449520 | Pepper | May 2013 | B2 |
8450079 | Kovalenko et al. | May 2013 | B2 |
8491178 | Breidenthal | Jul 2013 | B2 |
8492081 | Nichols | Jul 2013 | B2 |
8512754 | Needham | Aug 2013 | B2 |
8516714 | Biemans | Aug 2013 | B2 |
8518452 | Bjornstrup | Aug 2013 | B2 |
8529961 | Campbell et al. | Sep 2013 | B2 |
8598319 | Michel et al. | Dec 2013 | B2 |
8603063 | Grimm | Dec 2013 | B2 |
8858681 | Harp | Oct 2014 | B2 |
8951565 | McCarthy | Feb 2015 | B2 |
9011846 | Overholser et al. | Apr 2015 | B2 |
9046303 | Yagi | Jun 2015 | B2 |
9132206 | McCarthy | Sep 2015 | B2 |
9161527 | Cutting | Oct 2015 | B2 |
9469835 | Bronshtein | Oct 2016 | B2 |
9545379 | Liu | Jan 2017 | B2 |
9561184 | Khan | Feb 2017 | B2 |
9561893 | Root | Feb 2017 | B2 |
9696284 | Rannisto et al. | Jul 2017 | B2 |
9796273 | Ragazzini | Oct 2017 | B2 |
9863699 | Corbin, III | Jan 2018 | B2 |
9863701 | Robinson | Jan 2018 | B2 |
10058091 | Wolf | Aug 2018 | B2 |
10377520 | Root | Aug 2019 | B2 |
10492507 | Rizvi | Dec 2019 | B2 |
10507165 | Di Naro | Dec 2019 | B2 |
10539367 | Corbin, III | Jan 2020 | B2 |
10723497 | Diaz Guerrero | Jul 2020 | B2 |
10793327 | Weimer | Oct 2020 | B2 |
10830535 | Oprins et al. | Nov 2020 | B2 |
10844366 | Durance et al. | Nov 2020 | B2 |
11236942 | Christ | Feb 2022 | B2 |
11236943 | Christ | Feb 2022 | B2 |
20010004641 | Hawkins | Jun 2001 | A1 |
20010031721 | Webb et al. | Oct 2001 | A1 |
20020035354 | Mirle | Mar 2002 | A1 |
20020146409 | Herring et al. | Oct 2002 | A1 |
20030065149 | McGinnis | Apr 2003 | A1 |
20030068416 | Burgess et al. | Apr 2003 | A1 |
20030080056 | Boos et al. | May 2003 | A1 |
20030104508 | Gempeler et al. | Jun 2003 | A1 |
20030134418 | Mitaka | Jul 2003 | A1 |
20030143566 | Helftenbein | Jul 2003 | A1 |
20040005310 | Rapp et al. | Jan 2004 | A1 |
20040081588 | Hammerstedt | Apr 2004 | A1 |
20040126880 | Manders et al. | Jul 2004 | A1 |
20040132207 | Arima et al. | Jul 2004 | A1 |
20050158856 | Edelson et al. | Jul 2005 | A1 |
20050170068 | Roodink et al. | Aug 2005 | A1 |
20050282734 | Kadima et al. | Dec 2005 | A1 |
20060004189 | Gandy | Jan 2006 | A1 |
20060134084 | Wolkers et al. | Jun 2006 | A1 |
20060182652 | Burgess et al. | Aug 2006 | A1 |
20060216687 | Alves-Filho | Sep 2006 | A1 |
20060263759 | Alves-Filho | Nov 2006 | A1 |
20070014780 | Woolverton | Jan 2007 | A1 |
20070110817 | Shestakov | May 2007 | A1 |
20070116599 | Walters et al. | May 2007 | A1 |
20070135343 | Webb et al. | Jun 2007 | A1 |
20070166389 | Bakaltcheva | Jul 2007 | A1 |
20070275028 | Barry et al. | Nov 2007 | A1 |
20080038818 | Natan et al. | Feb 2008 | A1 |
20080063697 | Bedard | Mar 2008 | A1 |
20080256822 | Suzuki | Apr 2008 | A1 |
20080119818 | Bakaltcheva | May 2008 | A1 |
20080145444 | Merchant et al. | Jun 2008 | A1 |
20080193386 | Yoo et al. | Aug 2008 | A1 |
20080206293 | Toreki | Aug 2008 | A1 |
20080234653 | McCarthy | Sep 2008 | A1 |
20080234654 | McCarthy | Sep 2008 | A1 |
20080249499 | Vancaillie | Oct 2008 | A1 |
20080299212 | Kim et al. | Dec 2008 | A1 |
20090036862 | Grimm | Feb 2009 | A1 |
20090107001 | McCarthy | Apr 2009 | A1 |
20090113753 | Pepper | May 2009 | A1 |
20090223080 | McCarthy | Sep 2009 | A1 |
20090324929 | Yamakawa | Dec 2009 | A1 |
20100049156 | Dickhorner | Feb 2010 | A1 |
20100144595 | Bucci | Jun 2010 | A1 |
20100159023 | Bjornstrup | Jun 2010 | A1 |
20100168018 | Pikal et al. | Jul 2010 | A1 |
20110008458 | Gandy et al. | Jan 2011 | A1 |
20110008459 | Marguerre et al. | Jan 2011 | A1 |
20110020299 | Bader | Jan 2011 | A1 |
20110114524 | Eibl | May 2011 | A1 |
20110142948 | Langer et al. | Jun 2011 | A1 |
20110144613 | Pepper | Jun 2011 | A1 |
20110177541 | Martinoli et al. | Jul 2011 | A1 |
20110183311 | Ho | Jul 2011 | A1 |
20110263408 | Suto et al. | Oct 2011 | A1 |
20110282325 | Gregory | Nov 2011 | A1 |
20120027867 | Fischer et al. | Feb 2012 | A1 |
20120040384 | Stangier | Feb 2012 | A1 |
20120045518 | Nielsen et al. | Feb 2012 | A1 |
20120070855 | Mirshahi et al. | Mar 2012 | A1 |
20120141595 | Tseng et al. | Jun 2012 | A1 |
20120156306 | Weissman et al. | Jun 2012 | A1 |
20120231485 | Onundarson | Sep 2012 | A1 |
20120252044 | Rechner et al. | Oct 2012 | A1 |
20120329082 | Viola et al. | Dec 2012 | A1 |
20130008048 | Patel et al. | Jan 2013 | A1 |
20130019572 | Beator et al. | Jan 2013 | A1 |
20130030161 | Anitua Aldecoa | Jan 2013 | A1 |
20130040890 | Guo et al. | Feb 2013 | A1 |
20130090291 | Gulle et al. | Apr 2013 | A1 |
20130116410 | Ivarsson et al. | May 2013 | A1 |
20130122107 | Bakaltcheva | May 2013 | A1 |
20130126370 | DiLiberto et al. | May 2013 | A1 |
20130143198 | Sailliol | Jun 2013 | A1 |
20130149727 | Aygen | Jun 2013 | A1 |
20130183661 | Prante et al. | Jul 2013 | A1 |
20130195897 | Teschner et al. | Aug 2013 | A1 |
20130195959 | Patel | Aug 2013 | A1 |
20130202585 | Bardat et al. | Aug 2013 | A1 |
20130243877 | Haley et al. | Sep 2013 | A1 |
20130251695 | Farmer et al. | Sep 2013 | A1 |
20130303842 | Zeitels et al. | Nov 2013 | A1 |
20130316011 | Ahn et al. | Nov 2013 | A1 |
20130326899 | Yagi | Dec 2013 | A1 |
20140178513 | Matthews | Jun 2014 | A1 |
20140212895 | Lim | Jul 2014 | A1 |
20140259724 | McCarthy | Sep 2014 | A1 |
20140287643 | Nozaki | Sep 2014 | A1 |
20140360891 | Kline | Dec 2014 | A1 |
20150158652 | Root | Jun 2015 | A1 |
20150354894 | Corbin, III | Dec 2015 | A1 |
20160084572 | Khan | Mar 2016 | A1 |
20160375184 | Albert | Dec 2016 | A1 |
20170100339 | Liu | Apr 2017 | A1 |
20170113824 | Root | Apr 2017 | A1 |
20170203871 | Murto | Jul 2017 | A1 |
20170258877 | Bare et al. | Sep 2017 | A1 |
20170259186 | Khan | Sep 2017 | A1 |
20170367322 | Liu et al. | Dec 2017 | A1 |
20180128544 | Corbin, III | May 2018 | A1 |
20180221418 | Daniel | Aug 2018 | A1 |
20190000979 | Cleek et al. | Jan 2019 | A1 |
20190030169 | Ivarsson et al. | Jan 2019 | A1 |
20190106254 | Weimer | Apr 2019 | A1 |
20190142694 | Di Naro | May 2019 | A1 |
20200253826 | Qiu | Aug 2020 | A1 |
20200288703 | Parakin | Sep 2020 | A1 |
20200289728 | Johnson et al. | Sep 2020 | A1 |
20200292231 | Johnson et al. | Sep 2020 | A1 |
20210016943 | Weimer | Jan 2021 | A1 |
20210127663 | Paukkonen | May 2021 | A1 |
Number | Date | Country |
---|---|---|
517248 | Jul 1981 | AU |
590193 | Nov 1989 | AU |
622133 | Apr 1992 | AU |
8165698 | Jan 2000 | AU |
744025 | Feb 2002 | AU |
2002326819 | Apr 2003 | AU |
2007205748 | Nov 2009 | AU |
2012205238 | Aug 2012 | AU |
64922 | Sep 2006 | BG |
745958 | Nov 1966 | CA |
780792 | Mar 1968 | CA |
787838 | Jun 1968 | CA |
835939 | Mar 1970 | CA |
843883 | Jun 1970 | CA |
1260389 | Sep 1989 | CA |
1210267 | Mar 1999 | CN |
1242429 | Jan 2000 | CN |
1376520 | Oct 2002 | CN |
1410537 | Apr 2003 | CN |
1156282 | Jul 2004 | CN |
1157194 | Jul 2004 | CN |
1162160 | Aug 2004 | CN |
1187616 | Feb 2005 | CN |
1220512 | Sep 2005 | CN |
1745627 | Mar 2006 | CN |
1250718 | Apr 2006 | CN |
1267340 | Aug 2006 | CN |
1270731 | Aug 2006 | CN |
1281161 | Oct 2006 | CN |
1931025 | Mar 2007 | CN |
101152211 | Apr 2008 | CN |
101216432 | Jul 2008 | CN |
101299029 | Nov 2008 | CN |
101310728 | Nov 2008 | CN |
100469359 | Mar 2009 | CN |
101416985 | Apr 2009 | CN |
100531723 | Aug 2009 | CN |
101579356 | Nov 2009 | CN |
100584942 | Jan 2010 | CN |
101618120 | Jan 2010 | CN |
101167745 | Jun 2010 | CN |
101766252 | Jul 2010 | CN |
101833009 | Sep 2010 | CN |
101879333 | Nov 2010 | CN |
101893628 | Nov 2010 | CN |
101893639 | Nov 2010 | CN |
101957364 | Jan 2011 | CN |
101971972 | Feb 2011 | CN |
101347617 | Apr 2011 | CN |
102000022 | Apr 2011 | CN |
102008504 | Apr 2011 | CN |
102012433 | Apr 2011 | CN |
102050876 | May 2011 | CN |
102078306 | Jun 2011 | CN |
102106872 | Jun 2011 | CN |
101433553 | Aug 2011 | CN |
102207504 | Oct 2011 | CN |
101385855 | Nov 2011 | CN |
102229670 | Nov 2011 | CN |
102241767 | Nov 2011 | CN |
102250238 | Nov 2011 | CN |
101461939 | Jan 2012 | CN |
102337252 | Feb 2012 | CN |
102363634 | Feb 2012 | CN |
102426240 | Apr 2012 | CN |
102426258 | Apr 2012 | CN |
101285086 | May 2012 | CN |
102435743 | May 2012 | CN |
101830979 | Jun 2012 | CN |
101843335 | Jun 2012 | CN |
102507934 | Jun 2012 | CN |
102512418 | Jun 2012 | CN |
102524812 | Jul 2012 | CN |
102552154 | Jul 2012 | CN |
102579737 | Jul 2012 | CN |
102590496 | Jul 2012 | CN |
102590529 | Jul 2012 | CN |
102600074 | Jul 2012 | CN |
102600231 | Jul 2012 | CN |
102600508 | Jul 2012 | CN |
101899110 | Aug 2012 | CN |
102614219 | Aug 2012 | CN |
102628869 | Aug 2012 | CN |
102645358 | Aug 2012 | CN |
101816789 | Sep 2012 | CN |
102688200 | Sep 2012 | CN |
102692514 | Sep 2012 | CN |
101900712 | Oct 2012 | CN |
102327289 | Oct 2012 | CN |
102697581 | Oct 2012 | CN |
102746396 | Oct 2012 | CN |
102754848 | Oct 2012 | CN |
102327288 | Nov 2012 | CN |
102793053 | Nov 2012 | CN |
101843289 | Dec 2012 | CN |
102854322 | Jan 2013 | CN |
102866220 | Jan 2013 | CN |
102866255 | Jan 2013 | CN |
102879560 | Jan 2013 | CN |
101948630 | Feb 2013 | CN |
102908321 | Feb 2013 | CN |
102908368 | Feb 2013 | CN |
102093385 | Mar 2013 | CN |
102228683 | Mar 2013 | CN |
102240310 | Mar 2013 | CN |
102988974 | Mar 2013 | CN |
102210854 | Apr 2013 | CN |
103007280 | Apr 2013 | CN |
103039693 | Apr 2013 | CN |
103054816 | Apr 2013 | CN |
101756013 | May 2013 | CN |
103076455 | May 2013 | CN |
103113456 | May 2013 | CN |
102258780 | Jun 2013 | CN |
102319425 | Jun 2013 | CN |
102525954 | Jun 2013 | CN |
102274493 | Aug 2013 | CN |
203572189 | Apr 2014 | CN |
106461327 | Feb 2017 | CN |
277138 | Nov 1992 | CS |
109659 | Nov 1974 | DE |
2430447 | Jan 1975 | DE |
112775 | May 1975 | DE |
2617742 | Jun 1977 | DE |
2617742 | Jun 1977 | DE |
2365629 | Jun 1983 | DE |
19729778 | Jan 1999 | DE |
19729778 | Jan 1999 | DE |
69521470 | May 2002 | DE |
69133198 | Jul 2003 | DE |
69810755 | Aug 2003 | DE |
105923 | Apr 1984 | EP |
121868 | Oct 1984 | EP |
0157579 | Oct 1985 | EP |
111777 | Mar 1987 | EP |
0124018 | Nov 1987 | EP |
204045 | Jan 1988 | EP |
0284249 | Sep 1988 | EP |
0284249 | Sep 1988 | EP |
0335682 | Oct 1989 | EP |
0335682 | Oct 1989 | EP |
0343596 | Nov 1989 | EP |
0343596 | Nov 1989 | EP |
0343596 | Nov 1989 | EP |
206448 | Nov 1990 | EP |
215050 | Feb 1991 | EP |
445108 | Sep 1991 | EP |
392377 | Feb 1995 | EP |
593176 | Mar 1995 | EP |
2729932 | Aug 1996 | EP |
2729932 | Aug 1996 | EP |
752097 | Jan 1997 | EP |
485377 | May 1999 | EP |
1021726 | Jul 2000 | EP |
1171163 | Jan 2002 | EP |
1243275 | Sep 2002 | EP |
1286706 | Mar 2003 | EP |
876155 | Jul 2004 | EP |
1087990 | Sep 2004 | EP |
1087990 | Sep 2004 | EP |
1113269 | Oct 2006 | EP |
1870649 | Dec 2007 | EP |
997735 | Jan 2008 | EP |
1958618 | Aug 2008 | EP |
1958618 | Aug 2008 | EP |
1730299 | Jun 2011 | EP |
2371343 | Dec 2011 | EP |
2431024 | Mar 2012 | EP |
2431024 | Mar 2012 | EP |
2564481 | Mar 2013 | EP |
2574350 | Apr 2013 | EP |
1407780 | May 2013 | EP |
1407780 | May 2013 | EP |
3290064 | Mar 2018 | EP |
2001727 | Oct 1969 | FR |
2160285 | Jun 1973 | FR |
2187909 | Jan 1974 | FR |
2224118 | Oct 1974 | FR |
2227276 | Nov 1974 | FR |
2363577 | Mar 1978 | FR |
2475737 | Aug 1981 | FR |
2600998 | Jan 1988 | FR |
2717782 | Sep 1995 | FR |
2729932 | Aug 1996 | FR |
2814239 | Mar 2002 | FR |
2963556 | Feb 2012 | FR |
353286 | Jul 1931 | GB |
425567 | Mar 1935 | GB |
450146 | Jul 1936 | GB |
450146 | Jul 1936 | GB |
491515 | Sep 1938 | GB |
620573 | Mar 1949 | GB |
727148 | Mar 1955 | GB |
731104 | Jun 1955 | GB |
748784 | May 1956 | GB |
748784 | May 1956 | GB |
770075 | Mar 1957 | GB |
807781 | Jan 1959 | GB |
814491 | Jun 1959 | GB |
814491 | Jun 1959 | GB |
853288 | Nov 1960 | GB |
859609 | Jan 1961 | GB |
906860 | Sep 1962 | GB |
911181 | Nov 1962 | GB |
917012 | Jan 1963 | GB |
941019 | Nov 1963 | GB |
979759 | Jan 1965 | GB |
1003748 | Sep 1965 | GB |
1073172 | Jun 1967 | GB |
1074461 | Jul 1967 | GB |
1186544 | Apr 1970 | GB |
1206033 | Sep 1970 | GB |
1206033 | Sep 1970 | GB |
1222810 | Feb 1971 | GB |
1266274 | Mar 1972 | GB |
1337178 | Nov 1973 | GB |
1372812 | Nov 1974 | GB |
1391746 | Apr 1975 | GB |
1480092 | Jul 1977 | GB |
1486787 | Sep 1977 | GB |
1486787 | Sep 1977 | GB |
1497517 | Jan 1978 | GB |
1507435 | Apr 1978 | GB |
1524712 | Sep 1978 | GB |
1530748 | Nov 1978 | GB |
1536725 | Dec 1978 | GB |
1551792 | Aug 1979 | GB |
1551928 | Sep 1979 | GB |
1563839 | Apr 1980 | GB |
2148090 | Jul 1987 | GB |
2167856 | Dec 1988 | GB |
2564481 | Jan 2019 | GB |
1064142 | Feb 1985 | IT |
S52156921 | Dec 1977 | JP |
S53091117 | Aug 1978 | JP |
S5426961 | Feb 1979 | JP |
S5571452 | May 1980 | JP |
S56127307 | Oct 1981 | JP |
S56127308 | Oct 1981 | JP |
S56160991 | Dec 1981 | JP |
S5772911 | May 1982 | JP |
S57122796 | Jul 1982 | JP |
S57142561 | Sep 1982 | JP |
S57159561 | Oct 1982 | JP |
S58131566 | Aug 1983 | JP |
S59088042 | May 1984 | JP |
S59136657 | Aug 1984 | JP |
S59181224 | Oct 1984 | JP |
S59212768 | Dec 1984 | JP |
S59218960 | Dec 1984 | JP |
S60168051 | Aug 1985 | JP |
S61040752 | Feb 1986 | JP |
S61053567 | Mar 1986 | JP |
S61128974 | Jun 1986 | JP |
S61155332 | Jul 1986 | JP |
S61225652 | Oct 1986 | JP |
S61282054 | Dec 1986 | JP |
S62010019 | Jan 1987 | JP |
S62138433 | Jun 1987 | JP |
H63-036828 | Feb 1988 | JP |
H63-036828 | Feb 1988 | JP |
S63157936 | Jun 1988 | JP |
1021741 | Apr 1989 | JP |
H1247060 | Oct 1989 | JP |
H2221859 | Sep 1990 | JP |
H07270405 | Oct 1995 | JP |
H09020687 | Jan 1997 | JP |
H09222427 | Aug 1997 | JP |
2657092 | Sep 1997 | JP |
H1045616 | Feb 1998 | JP |
H10108907 | Apr 1998 | JP |
H10-165480 | Jun 1998 | JP |
3140797 | Mar 2001 | JP |
3142192 | Mar 2001 | JP |
3219181 | Oct 2001 | JP |
2002029977 | Jan 2002 | JP |
2002052067 | Feb 2002 | JP |
3292760 | Jun 2002 | JP |
3365091 | Jan 2003 | JP |
2003055256 | Feb 2003 | JP |
2003055257 | Feb 2003 | JP |
2003-144523 | May 2003 | JP |
2003339346 | Dec 2003 | JP |
2004049493 | Feb 2004 | JP |
3543144 | Jul 2004 | JP |
3712989 | Nov 2005 | JP |
2006036749 | Feb 2006 | JP |
2007197353 | Aug 2007 | JP |
4024506 | Dec 2007 | JP |
4059299 | Mar 2008 | JP |
2006545011 | May 2008 | JP |
2008527741 | Jul 2008 | JP |
2009297212 | Dec 2009 | JP |
2010266086 | Nov 2010 | JP |
2011239 | Jan 2011 | JP |
2011120763 | Jun 2011 | JP |
2012051895 | Mar 2012 | JP |
5002106 | Aug 2012 | JP |
5037621 | Oct 2012 | JP |
5049447 | Oct 2012 | JP |
5087815 | Dec 2012 | JP |
5252909 | Jul 2013 | JP |
5340945 | Nov 2013 | JP |
2014028661 | Feb 2014 | JP |
2014028661 | Feb 2014 | JP |
5960660 | Aug 2016 | JP |
2017-517335 | Jun 2017 | JP |
6219922 | Oct 2017 | JP |
6305870 | Apr 2018 | JP |
100197297 | Jun 1999 | KR |
20000020804 | Apr 2000 | KR |
100503629 | Jul 2005 | KR |
20060005770 | Jan 2006 | KR |
100631188 | Oct 2006 | KR |
100767541 | Oct 2007 | KR |
100857273 | Sep 2008 | KR |
100908742 | Jul 2009 | KR |
20110008382 | Jan 2011 | KR |
101157096 | Jun 2012 | KR |
101200423 | Nov 2012 | KR |
20130009161 | Jan 2013 | KR |
20130034991 | Apr 2013 | KR |
20130053609 | May 2013 | KR |
2011202 | Apr 1994 | RU |
2028130 | Feb 1995 | RU |
2028133 | Feb 1995 | RU |
2080865 | Jun 1997 | RU |
2090165 | Sep 1997 | RU |
2090166 | Sep 1997 | RU |
2121364 | Nov 1998 | RU |
2193868 | Dec 2002 | RU |
2197267 | Jan 2003 | RU |
2242759 | Dec 2004 | RU |
2266542 | Dec 2005 | RU |
2273026 | Mar 2006 | RU |
2314527 | Jan 2008 | RU |
2322243 | Apr 2008 | RU |
2332666 | Aug 2008 | RU |
2325655 | Nov 2008 | RU |
2357252 | May 2009 | RU |
2426548 | Aug 2011 | RU |
2442984 | Feb 2012 | RU |
2455014 | Jul 2012 | RU |
2456602 | Jul 2012 | RU |
2463063 | Oct 2012 | RU |
2012137892 | Feb 2013 | RU |
2478958 | Apr 2013 | RU |
2492867 | Sep 2013 | RU |
548275 | Feb 1977 | SU |
654238 | Mar 1979 | SU |
686732 | Sep 1979 | SU |
700129 | Nov 1979 | SU |
786954 | Dec 1980 | SU |
1344354 | Oct 1987 | SU |
1592717 | Sep 1990 | SU |
1678371 | Sep 1991 | SU |
1716443 | Feb 1992 | SU |
1752187 | Jul 1992 | SU |
200600103 | Jan 2006 | TW |
I358264 | Feb 2012 | TW |
26543 | Sep 2007 | UA |
WO-1992013495 | Aug 1992 | WO |
WO-1992014360 | Sep 1992 | WO |
WO-1995012127 | May 1995 | WO |
WO-1995015763 | Jun 1995 | WO |
9527180 | Oct 1995 | WO |
WO-9527180 | Oct 1995 | WO |
9629556 | Sep 1996 | WO |
WO-9629556 | Sep 1996 | WO |
9631748 | Oct 1996 | WO |
WO-9631748 | Oct 1996 | WO |
WO-1997046883 | Dec 1997 | WO |
0036353 | Jun 2000 | WO |
WO-0036353 | Jun 2000 | WO |
WO-2000-036353 | Jun 2000 | WO |
WO-2000047187 | Aug 2000 | WO |
WO-2001064228 | Sep 2001 | WO |
WO-2002083157 | Oct 2002 | WO |
WO-2002083737 | Oct 2002 | WO |
WO-2002087540 | Nov 2002 | WO |
WO-2003082310 | Oct 2003 | WO |
WO 2005089816 | Sep 2005 | WO |
2006000422 | Jan 2006 | WO |
WO-2006000422 | Jan 2006 | WO |
2006028648 | Mar 2006 | WO |
WO-2006028648 | Mar 2006 | WO |
WO-2006054519 | May 2006 | WO |
2006028648 | Jan 2007 | WO |
WO-2006028648 | Jan 2007 | WO |
2007104760 | Sep 2007 | WO |
WO-2007104760 | Sep 2007 | WO |
WO-2007104760 | Apr 2008 | WO |
2008115548 | Sep 2008 | WO |
WO-2008108549 | Sep 2008 | WO |
WO-2008115548 | Sep 2008 | WO |
2008130602 | Oct 2008 | WO |
WO-2008-130602 | Oct 2008 | WO |
WO-2008130602 | Oct 2008 | WO |
2010019217 | Feb 2010 | WO |
WO-2010019217 | Feb 2010 | WO |
2010033169 | Mar 2010 | WO |
WO-2010033169 | Mar 2010 | WO |
2010093429 | Aug 2010 | WO |
WO-2010093429 | Aug 2010 | WO |
WO-2012092712 | Jul 2012 | WO |
WO-2012098358 | Jul 2012 | WO |
WO-2012101109 | Aug 2012 | WO |
WO-2012140209 | Oct 2012 | WO |
WO-2012159075 | Nov 2012 | WO |
WO-2013013537 | Jan 2013 | WO |
WO-2013042868 | Mar 2013 | WO |
WO-2013057219 | Apr 2013 | WO |
2013062479 | May 2013 | WO |
WO-2013-062479 | May 2013 | WO |
WO-2013062479 | May 2013 | WO |
WO-2013076507 | May 2013 | WO |
WO-2013085502 | Jun 2013 | WO |
2014033228 | Mar 2014 | WO |
WO-2014033228 | Mar 2014 | WO |
2014165222 | Oct 2014 | WO |
WO-2014-165222 | Oct 2014 | WO |
WO-2014165222 | Oct 2014 | WO |
2015191599 | Dec 2015 | WO |
WO-2015191599 | Dec 2015 | WO |
2015191599 | Apr 2016 | WO |
WO-2015191599 | Apr 2016 | WO |
2019074886 | Apr 2019 | WO |
WO-2019074886 | Apr 2019 | WO |
WO 2020185909 | Sep 2020 | WO |
WO-2020242552 | Dec 2020 | WO |
Entry |
---|
US 8,359,766 B2, 01/2013, Hubbard, Jr. et al. (withdrawn) |
US 8,359,766, 01/2013. (withdrawn). |
Cherry, Christopher Lee Albert, “Development of Novel Containment Systems for Freeze-Drying,” a thesis submitted to Cardiff Metropolitan University, Apr. 10, 2013. |
Glassberg et al., “Freeze-dried Plasma at the Point of Injury: from Concept to Doctrine”, SHOCK, Dec. 2013, vol. 40, No. 6, pp. 444-450. |
Cherry, Chris, “Containment systems for freeze-drying,” ISL-FD, Sep. 7, 2015. |
Cannon, Jeremy W. M.D., “Prehospital Damage-Control Resuscitation”, The New England Journal of Medicine, Jul. 26, 2018, pp. 387-388. |
Sperry et al., “Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock”, The New England Journal of Medicine, Jul. 26, 2018, pp. 315-326. |
Soares, Jeffrey M., “Saving Lives with Freeze-dried Plasma”, The United States Army, Nov. 27, 2017, pp. 1-5. https://www.army.mil/article/197409. |
Pan et al, “Study of Banana Dehydration Using Sequential Infrared Radiation Heating and Freeze-Drying”, LWT—Food Science and Technology, 2008 v. 41, pp. 1944-1951. |
International Search Report and Written Opinion, PCT/US2018/054943, dated Jan. 25, 2019. |
Official Action for Canada Patent. Application No. 3078625, dated Jul. 16, 2021, 3 pages. |
Official Action (with English translation) for Japan Patent Application No. 2020-540696, dated Aug. 24, 2021, 17 pages. |
Official Action for U.S. Appl. No. 16/154,976, dated Dec. 20, 2019, 12 pages. |
Official Action for U.S. Appl. No. 16/154,976, dated Apr. 13, 2020, 9 pages. |
Notice of Allowance for U.S. Appl. No. 16/154,976, dated Jun. 12, 2020, 9 pages. |
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022113, dated Nov. 5, 2020, 45 pages. |
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022120, dated Nov. 26, 2020, 17 pages. |
Invitation to Pay Additional Fees for International (PCT) Patent Application No. PCT/US2020/022120, dated Oct. 1, 2020, 11 pages. |
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022128, dated Sep. 4, 2020, 12 pages. |
Official Action (with English abstract) for China Patent Application No. 201880064085.6, dated Jul. 15, 2021, 12 pages. |
Official Action for U.S. Appl. No. 16/815,843, dated Jun. 16, 2021, 11 pages. |
Notice of Allowance for U.S. Appl. No. 16/815,843, dated Sep. 24, 2021, 5 pages. |
Official Action (with English abstract) for Chinese Patent Application No. 201880064085.6, dated Mar. 11, 2022, 9 pages. |
Official Action (with English translation) for Japan Patent Application No. 2020-540696, dated Jan. 11, 2022, 16 pages. |
Official Action for U.S. Appl. No. 16/815,904, dated Feb. 7, 2022, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20210016943 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
62569858 | Oct 2017 | US | |
62571087 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16154976 | Oct 2018 | US |
Child | 17010083 | US |